70 results
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
your role, you should discuss these matters with the chairman.
TIME COMMITMENT
You will be expected to devote such time as is necessary for the proper … commitment. You may be required to devote additional time to the Company in respect of preparation time for meetings and ad hoc matters that may arise
8-K
EX-10.3
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
COMMITMENT
You will be expected to devote such time as is necessary for the proper performance of your duties. Overall we anticipate that you …
The nature of the role makes it impossible to be specific about the maximum time commitment. You may be required to devote additional time to the Company
8-K
EX-10.4
668zrx415ebvw fodkd
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
wenyme 2duj4
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-10.1
tkdxc1y
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-99.1
mv2 6pwrh0
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am